Joshi K, Muhith A, Obeid M, Milner-Watts C, et al. Safety monitoring of two and four-weekly adjuvant durvalumab for patients with stage III NSCLC: implications for the COVID-19 pandemic and beyond. Lung Cancer 2021;156:147-150.
PMID: 33965281